{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T08:43:10Z","timestamp":1790239390271,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2012,5,15]],"date-time":"2012-05-15T00:00:00Z","timestamp":1337040000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2012,5,15]],"date-time":"2012-05-15T00:00:00Z","timestamp":1337040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1038\/tpj.2012.13","type":"journal-article","created":{"date-parts":[[2012,5,15]],"date-time":"2012-05-15T11:20:20Z","timestamp":1337080820000},"page":"335-341","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Profiling of drug-metabolizing enzymes\/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin"],"prefix":"10.1038","volume":"13","author":[{"given":"I","family":"Iacobucci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Lonetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Candoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Sazzini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Papayannidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Formica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Ottaviani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Michelutti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Simeone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Astolfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M C","family":"Abbenante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Parisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Cattina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Malagola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Damiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Gherlinzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Gottardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Baccarani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Fanin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,5,15]]},"reference":[{"key":"BFtpj201213_CR1","first-page":"260","volume":"11","author":"J Deeken","year":"2009","unstructured":"Deeken J . The Affymetrix DMET platform and pharmacogenetics in drug development. Curr Opin Mol Ther 2009; 11: 260\u2013268.","journal-title":"Curr Opin Mol Ther"},{"key":"BFtpj201213_CR2","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/sj.tpj.6500308","volume":"5","author":"D Herman","year":"2005","unstructured":"Herman D, Locatelli I, Grabnar I, Peternel P, Stegnar M, Mrhar A et al. Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose. Pharmacogenomics J 2005; 5: 193\u2013202.","journal-title":"Pharmacogenomics J"},{"key":"BFtpj201213_CR3","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1172\/JCI30558","volume":"117","author":"Y Shu","year":"2007","unstructured":"Shu Y, Sheardown SA, Brown C, Owen RP, Zhang S, Castro RA et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest 2007; 117: 1422\u20131431.","journal-title":"J Clin Invest"},{"key":"BFtpj201213_CR4","doi-asserted-by":"publisher","first-page":"415","DOI":"10.2217\/14622416.9.4.415","volume":"9","author":"H Takane","year":"2008","unstructured":"Takane H, Shikata E, Otsubo K, Higuchi S, Ieiri I . Polymorphism in human organic cation transporters and metformin action. Pharmacogenomics 2008; 9: 415\u2013422.","journal-title":"Pharmacogenomics"},{"key":"BFtpj201213_CR5","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1056\/NEJMoa0808227","volume":"360","author":"T Simon","year":"2009","unstructured":"Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Meneveau N et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009; 360: 363\u2013375.","journal-title":"N Engl J Med"},{"key":"BFtpj201213_CR6","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0140-6736(08)61845-0","volume":"373","author":"JP Collet","year":"2009","unstructured":"Collet JP, Hulot JS, Pena A, Villard E, Esteve JB, Silvain J et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 2009; 373: 309\u2013317.","journal-title":"Lancet"},{"key":"BFtpj201213_CR7","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1056\/NEJMoa0809171","volume":"360","author":"JL Mega","year":"2009","unstructured":"Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: 354\u2013362.","journal-title":"N Engl J Med"},{"key":"BFtpj201213_CR8","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1158\/1078-0432.CCR-08-2006","volume":"15","author":"VO Dezentje","year":"2009","unstructured":"Dezentje VO, Guchelaar HJ, Nortier JW, van de Velde CJ, Gelderblom H . Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer. Clin Cancer Res 2009; 15: 15\u201321.","journal-title":"Clin Cancer Res"},{"key":"BFtpj201213_CR9","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1200\/JCO.2004.05.074","volume":"22","author":"WL Dahut","year":"2004","unstructured":"Dahut WL, Gulley JL, Arlen PM, Liu Y, Fedenko KM, Steinberg SM et al. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 2004; 22: 2532\u20132539.","journal-title":"J Clin Oncol"},{"key":"BFtpj201213_CR10","doi-asserted-by":"publisher","first-page":"4106","DOI":"10.1182\/blood-2007-11-122010","volume":"111","author":"MD Caldwell","year":"2008","unstructured":"Caldwell MD, Awad T, Johnson JA, Gage BF, Falkowski M, Gardina P et al. CYP4F2 genetic variant alters required warfarin dose. Blood 2008; 111: 4106\u20134112.","journal-title":"Blood"},{"key":"BFtpj201213_CR11","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/tpj.2009.57","volume":"10","author":"JF Deeken","year":"2009","unstructured":"Deeken JF, Cormier T, Price DK, Sissung TM, Steinberg SM, Tran K et al. A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform. Pharmacogenomics J 2009; 10: 191\u2013199.","journal-title":"Pharmacogenomics J"},{"key":"BFtpj201213_CR12","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1182\/blood-2005-05-2174","volume":"106","author":"N Boissel","year":"2005","unstructured":"Boissel N, Renneville A, Biggio V, Philippe N, Thomas X, Cayuela JM et al. Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype. Blood 2005; 106: 3618\u20133620.","journal-title":"Blood"},{"key":"BFtpj201213_CR13","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1182\/blood-2002-03-0990","volume":"100","author":"C Preudhomme","year":"2002","unstructured":"Preudhomme C, Sagot C, Boissel N, Cayuela JM, Tigaud I, de Botton S et al. Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood 2002; 100: 2717\u20132723.","journal-title":"Blood"},{"key":"BFtpj201213_CR14","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1038\/sj.leu.2402622","volume":"16","author":"N Boissel","year":"2002","unstructured":"Boissel N, Cayuela JM, Preudhomme C, Thomas X, Grardel N, Fund X et al. Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy. Leukemia 2002; 16: 1699\u20131704.","journal-title":"Leukemia"},{"key":"BFtpj201213_CR15","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1038\/leu.2011.97","volume":"25","author":"S Schnittger","year":"2011","unstructured":"Schnittger S, Bacher U, Kern W, Alpermann T, Haferlach C, Haferlach T . Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia. Leukemia 2011; 25: 1297\u20131304.","journal-title":"Leukemia"},{"key":"BFtpj201213_CR16","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.ctrv.2010.05.002","volume":"36","author":"U Bacher","year":"2010","unstructured":"Bacher U, Kohlmann A, Haferlach T . Gene expression profiling for diagnosis and therapy in acute leukaemia and other haematologic malignancies. Cancer Treat Rev 2010; 36: 637\u2013646.","journal-title":"Cancer Treat Rev"},{"key":"BFtpj201213_CR17","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1056\/NEJMoa031046","volume":"350","author":"L Bullinger","year":"2004","unstructured":"Bullinger L, Dohner K, Bair E, Frohling S, Schlenk RF, Tibshirani R et al. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med 2004; 350: 1605\u20131616.","journal-title":"N Engl J Med"},{"key":"BFtpj201213_CR18","first-page":"1086","volume":"94","author":"CP Leith","year":"1999","unstructured":"Leith CP, Kopecky KJ, Chen IM, Eijdems L, Slovak ML, McConnell TS et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1\/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood 1999; 94: 1086\u20131099.","journal-title":"Blood"},{"key":"BFtpj201213_CR19","first-page":"825","volume":"91","author":"D Damiani","year":"2006","unstructured":"Damiani D, Tiribelli M, Calistri E, Geromin A, Chiarvesio A, Michelutti A et al. The prognostic value of P-glycoprotein (ABCB) and breast cancer resistance protein (ABCG2) in adults with de novo acute myeloid leukemia with normal karyotype. Haematologica 2006; 91: 825\u2013828.","journal-title":"Haematologica"},{"key":"BFtpj201213_CR20","first-page":"1165","volume":"34","author":"JH Song","year":"2009","unstructured":"Song JH, Kim SH, Kweon SH, Lee TH, Kim HJ, Kim TS . Defective expression of deoxycytidine kinase in cytarabine-resistant acute myeloid leukemia cells. Int J Oncol 2009; 34: 1165\u20131171.","journal-title":"Int J Oncol"},{"key":"BFtpj201213_CR21","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1124\/jpet.107.128595","volume":"323","author":"JK Lamba","year":"2007","unstructured":"Lamba JK, Crews K, Pounds S, Schuetz EG, Gresham J, Gandhi V et al. Pharmacogenetics of deoxycytidine kinase: identification and characterization of novel genetic variants. J Pharmacol Exp Ther 2007; 323: 935\u2013945.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFtpj201213_CR22","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1038\/leu.2009.113","volume":"23","author":"U Mahlknecht","year":"2009","unstructured":"Mahlknecht U, Dransfeld CL, Bulut N, Kramer M, Thiede C, Ehninger G et al. SNP analyses in cytarabine metabolizing enzymes in AML patients and their impact on treatment response and patient survival: identification of CDA SNP C-451T as an independent prognostic parameter for survival. Leukemia 2009; 23: 1929\u20131932.","journal-title":"Leukemia"},{"key":"BFtpj201213_CR23","first-page":"1490","volume":"7","author":"PF Bross","year":"2001","unstructured":"Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 2001; 7: 1490\u20131496.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"BFtpj201213_CR24","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1182\/asheducation-2005.1.143","volume":"2005","author":"M. S. Tallman","year":"2005","unstructured":"Tallman MS . New strategies for the treatment of acute myeloid leukemia including antibodies and other novel agents. Hematology Am Soc Hematol Educ Program 2005: 143\u2013150.","journal-title":"Hematology"},{"key":"BFtpj201213_CR25","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/978-1-60761-663-4_7","volume":"632","author":"JK Burmester","year":"2010","unstructured":"Burmester JK, Sedova M, Shapero MH, Mansfield E . DMET microarray technology for pharmacogenomics-based personalized medicine. Methods Mol Biol 2010; 632: 99\u2013124.","journal-title":"Methods Mol Biol"},{"key":"BFtpj201213_CR26","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1093\/hmg\/ddl460","volume":"16","author":"X Luo","year":"2007","unstructured":"Luo X, Kranzler HR, Zuo L, Wang S, Schork NJ, Gelernter J . Multiple ADH genes modulate risk for drug dependence in both African- and European-Americans. Hum Mol Genet 2007; 16: 380\u2013390.","journal-title":"Hum Mol Genet"},{"key":"BFtpj201213_CR27","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1093\/hmg\/ddp060","volume":"18","author":"AJ Birley","year":"2009","unstructured":"Birley AJ, James MR, Dickson PA, Montgomery GW, Heath AC, Martin NG et al. ADH single nucleotide polymorphism associations with alcohol metabolism in vivo. Hum Mol Genet 2009; 18: 1533\u20131542.","journal-title":"Hum Mol Genet"},{"key":"BFtpj201213_CR28","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/j.1751-2980.2011.00480.x","volume":"12","author":"M Salaspuro","year":"2011","unstructured":"Salaspuro M . Acetaldehyde and gastric cancer. J Dig Dis 2011; 12: 51\u201359.","journal-title":"J Dig Dis"},{"key":"BFtpj201213_CR29","doi-asserted-by":"publisher","first-page":"4252","DOI":"10.1111\/j.1742-4658.2011.08357.x","volume":"278","author":"L Knockaert","year":"2011","unstructured":"Knockaert L, Fromenty B, Robin MA . Mechanisms of mitochondrial targeting of cytochrome P450 2E1: physiopathological role in liver injury and obesity. FEBS J 2011; 278: 4252\u20134260.","journal-title":"FEBS J"},{"key":"BFtpj201213_CR30","first-page":"300","volume":"24","author":"J Zhang","year":"2011","unstructured":"Zhang J, Yin L, Liang G, Liu R, Fan K, Pu Y . Detection of CYP2E1, a genetic biomarker of susceptibility to benzene metabolism toxicity in immortal human lymphocytes derived from the Han Chinese Population. Biomed Environ Sci 2011; 24: 300\u2013309.","journal-title":"Biomed Environ Sci"},{"key":"BFtpj201213_CR31","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1056\/NEJMoa0801936","volume":"359","author":"E Link","year":"2008","unstructured":"Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F et al. SLCO1B1 variants and statin-induced myopathy--a genomewide study. N Engl J Med 2008; 359: 789\u2013799.","journal-title":"N Engl J Med"},{"key":"BFtpj201213_CR32","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/art.21499","volume":"54","author":"J Graessler","year":"2006","unstructured":"Graessler J, Graessler A, Unger S, Kopprasch S, Tausche AK, Kuhlisch E et al. Association of the human urate transporter 1 with reduced renal uric acid excretion and hyperuricemia in a German Caucasian population. Arthritis Rheum 2006; 54: 292\u2013300.","journal-title":"Arthritis Rheum"},{"key":"BFtpj201213_CR33","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1210\/jc.2004-1111","volume":"90","author":"N Wakida","year":"2005","unstructured":"Wakida N, Tuyen DG, Adachi M, Miyoshi T, Nonoguchi H, Oka T et al. Mutations in human urate transporter 1 gene in presecretory reabsorption defect type of familial renal hypouricemia. J Clin Endocrinol Metab 2005; 90: 2169\u20132174.","journal-title":"J Clin Endocrinol Metab"}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/tpj201213.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/tpj201213","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/tpj201213.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T10:32:50Z","timestamp":1647945170000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/tpj201213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,15]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["BFtpj201213"],"URL":"https:\/\/doi.org\/10.1038\/tpj.2012.13","relation":{},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"value":"1470-269X","type":"print"},{"value":"1473-1150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,15]]},"assertion":[{"value":"26 January 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2012","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2012","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2012","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}